Company news
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) news
Every Cadrenal Therapeutics, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Cadrenal Therapeutics to Participate in H.C. Wainwright's 28th Annual Global Investment Conference
September 3, 2026
Cadrenal Therapeutics Announces Positive Outcome from FDA Type D Meeting for Phase 3 Registration Study of CAD-1005 in Heparin-Induced Th...
August 31, 2026
Cadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franc...
August 13, 2026
Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following La...
July 21, 2026
Cadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 1...
July 13, 2026
Cadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
June 30, 2026
Cadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
June 24, 2026
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to A...
June 15, 2026
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
June 3, 2026
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
May 19, 2026
Cadrenal Therapeutics Reports First Quarter 2026 Financial Results and Provides Phase 3 Development Update on CAD-1005 Following End-of-P...
May 7, 2026
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced...
April 30, 2026
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results, Provides Corporate Update on CAD-1005 Program for HIT Following End-...
April 1, 2026
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-...
March 31, 2026
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
March 12, 2026
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
March 2, 2026
CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events
February 25, 2026
Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical...
February 24, 2026
CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)
February 20, 2026
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan ...
January 12, 2026
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan ...
January 12, 2026
Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francis...
December 17, 2025
Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)
December 11, 2025
Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors
December 1, 2025
Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award
November 19, 2025
Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 10, 2025
CVKD: Acquires Factor XIa Inhibitors…
September 30, 2025
Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025
September 29, 2025
Cadrenal Therapeutics Enhances Anticoagulation Pipeline through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors
September 16, 2025
Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors
September 15, 2025
Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 11, 2025
Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitio...
August 5, 2025
Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients
June 12, 2025
Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025
June 4, 2025
CVKD: Preparations Continue for Phase 3 Trial of Tecarfarin…
May 19, 2025
Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness
May 15, 2025
Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update
May 8, 2025
Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq
April 17, 2025
Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences
April 3, 2025
Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin
March 13, 2025
Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate ...
March 4, 2025
Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin
February 6, 2025
Cadrenal Therapeutics to Present at BIO CEO & Investor Conference
February 5, 2025
Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
January 9, 2025
Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare ...
December 31, 2024
Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner M...
December 18, 2024
Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook
November 19, 2024
CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS
November 12, 2024
CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE
November 7, 2024
Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds
November 1, 2024